Alzheimer’s Drug Discovery Foundation | StartUp Health NOW Podcast

Podcast: Play in new window | Download (Duration: 29:14 — 26.8MB)

Unlocking Innovation: The Alzheimer’s Insights AI Prize and Its Impact on Healthcare

There are currently more than 55 million people worldwide living with Alzheimer’s disease and related dementias. Recent breakthroughs in new treatments and diagnostics provide hope, but there is potential to accelerate the pace of discovery and development.

Last year, StartUp Health, in partnership with the Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator (DxA) and Gates Ventures, the private office of Bill Gates, launched the Alzheimer’s Moonshot. This initiative breaks down silos and fosters meaningful collaboration between mission-aligned founders, funders, and partners, accelerating progress in preventing, managing, and curing Alzheimer’s and related dementias through the support of entrepreneurial innovation.

Now, the Alzheimer’s Disease Data Initiative (AD Data Initiative) is backing visionary AI solutions to accelerate Alzheimer’s research with the launch of a new million-dollar prize competition. The goal is to leverage agentic AI – AI that can plan, reason, and act autonomously – to help drive breakthroughs in Alzheimer’s disease and related dementias research.

Gregory Moore, MD, PhD, senior advisor to Gates Ventures and the Alzheimer’s Disease Data Initiative, sat down with us to share how you can join the competition to harness AI to radically accelerate Alzheimer’s disease research. The Alzheimer’s Insights AI Prize offers $1M to the winner for the agentic AI solution that can generate a powerful leap in the pace, scale, and reach of ADRD research.

Drawing from his unique background in both engineering and medicine, Dr. Moore discusses how AI could dramatically accelerate drug discovery and clinical trials by up to 50%. The initiative aims to break down traditional research barriers by harmonizing diverse data sets, from genomics to neuroimaging, making breakthroughs more accessible to the global scientific community.

The Alzheimer’s Insights AI Prize competition semi-finalist teams will be selected to present at a pitch event alongside the Clinical Trials on Alzheimer’s Disease (CTAD) Conference in San Diego this December, where innovators worldwide will present their ideas to a distinguished panel of judges from tech, academia, and venture capital. From there, up to three finalist teams will be invited to a final event at the AD/PD International Conference next March in Copenhagen, Denmark. With travel support available for participants, this initiative ensures global accessibility and collaboration.

Ready to learn how AI could revolutionize brain health research to potentially detect Alzheimer’s earlier, improve treatments, and work toward prevention and cures? Listen to this inspiring episode that bridges technology and medicine in the fight against dementia. Then visit Alzheimer’s Insights AI Prize to learn more and apply by September 12, 2025.

Do you want to participate in live conversations with industry luminaries? Members of our Health Moonshot Communities are leading startups with breakthrough technology-driven solutions for the world’s biggest health challenges. Fireside Chats, Expert Office Hours, and Peer Circles are benefits of our Health Moonshot Community Membership. To get involved, submit our three-minute application. If you’re mission-driven, collaborative, and ready to contribute as much as you gain, you might be the perfect fit.
» Learn more and apply today.

Want more content like this? Sign up for StartUp Health Insider™ to get funding insights, news, and special updates delivered to your inbox.

Podcast: Play in new window | Download (27.9MB)

“Academia is a great area and fosters innovation, but then taking that science and translating it into something that can actually impact human health has a number of challenges. So trying to understand what those barriers are and how we can help bridge them is something that we have been able to do at ADDF and in collaboration with StartUp Health.”

In this episode of StartUp Health NOW, we chat with Laura Nisenbaum, PhD, Executive Director of Drug Development at the Alzheimer’s Drug Discovery Foundation (ADDF). Organizations like ADDF are working to translate scientific research into real patient impact, particularly in the field of Alzheimer’s disease, by funding innovative ventures and supporting startups in the biotech space. Dr. Nisenbaum talks with us about new Alzheimer’s tests and therapeutics and pulls back the curtain on how ADDF supports startups.

Key Insights:

We are at a tipping point in Alzheimer’s. Our ability to predict and detect – and then treat – Alzheimer’s disease is growing faster than ever.
Dr. Laura Nisenbaum was involved in the launch of StartUp Health’s Alzheimer’s Moonshot, a collaboration with The Gates Foundation and ADDF, which is important for advancing research in the field of Alzheimer’s disease.
Academia fosters innovation, but translating scientific work into real patient impact poses challenges that need to be understood and bridged.
Venture philanthropy model enables funding for innovators who may not receive funding from for-profit companies, allowing for more risky endeavors.
The Diagnostics Accelerator challenges the research community to develop cutting-edge biomarkers and explore novel diagnostic technologies that will aid in Alzheimer’s diagnosis and clinical trial design.
The potential for AI to revolutionize Alzheimer’s research and diagnosis is evident in the funding and support for innovative companies in the field.
Focusing on the biology of aging, including inflammation and mitochondrial dysfunction, could be key in developing novel therapies for Alzheimer’s disease.
The field of Alzheimer’s research and care is at an amazing point with the first demonstration of some efficacy for drugs and a huge innovation curve from a biomarkers and diagnostics perspective.
We can now detect amyloid in the brain through blood tests, marking an amazing point of innovation in the field of Alzheimer’s research.
Pursue innovative ideas with great gusto and perseverance, and take advantage of the incredible network of mentors and collaborators to thrive in the biotech and startup space.
The momentum is building in the field of Alzheimer’s research, thanks to the support from organizations like ADDF.

Innovating in Alzheimer’s disease? Learn how you can join our Alzheimer’s Moonshot.

Want more content like this? Sign up for StartUp Health Insider™ to get funding insights, news, and special updates delivered to your inbox.

Innovators: Health Transformer University fuels your health moonshot

Funders: Become a Health Moonshot Champion

Tag Archives: Alzheimer’s Drug Discovery Foundation

Supercharging Alzheimer’s Research: Gates Ventures Backs a Million-Dollar AI Initiative

Unlocking Innovation: The Alzheimer’s Insights AI Prize and Its Impact on Healthcare

An Insider’s Perspective on the Near Future of Alzheimer’s Care